In Saudi Arabia, an increase in primary cases was observed during the months of January and February 2017.
Confirmed MERS patients were less than one percent of all tested persons in Saudi Arabia.
Twelve patients are currently under treatment at various hospitals in Saud Arabia.
This guidance document offers an algorithm on the public health investigation and management of possible cases of MERS-CoV.
This guidance document offers a risk assessment of MERS-CoV to UK residents and guidance for travellers to the Middle East on reducing the risk of getting MERS-CoV.
This resource offers a reference on middle east respiratory syndrome’s pathogenesis, case definitions, and clinical manifestations.
The vaccine may be useful to protect target animals as well as humans from MERS-CoV and RABV infections.
Researchers modified a rabies virus, so that it contains a protein from the Middle East Respiratory Syndrome (MERS) virus and rabies; creating a vaccine that protects mice against both rabies and MERS.
Researchers used data from travelers to the Middle East to estimate 3,250 (95% CI 1,300–6,600) severe MERS cases occurred during the period of September 2012–January 2016.
The US Biomedical Advanced Research and Development Authority (BARDA) and Regeneron Pharmaceuticals have partnered to develop a pair of antibodies to prevent and treat Middle East Respiratory Syndrome (MERS).